$MOH
MOLINA HEALTHCARE, INC. Stock $moh

$moh Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-Q Financial Statement

#000117992919000082 Filed on April 30, 2019

Income Statement

Concept	2019 Q1	2018 Q1
Revenue	$4.119B	$4.646B
YoY Change	-11.34%	-5.26%
Cost Of Revenue	$3.371B	$3.842B
YoY Change	-12.26%	-9.24%
Gross Profit	$581.0M	$615.0M
YoY Change	-5.53%	12.64%
Gross Profit Margin	14.11%	13.24%
Selling, General & Admin	$440.0M	$531.0M
YoY Change	-17.14%	-3.45%
% of Gross Profit	75.73%	86.34%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$25.00M	$37.00M
YoY Change	-32.43%	-24.49%
% of Gross Profit	4.3%	6.02%
Operating Expenses	$465.0M	$557.0M
YoY Change	-16.52%	-5.43%
Operating Profit	$280.0M	$222.0M
YoY Change	26.13%	170.73%
Interest Expense	$23.00M	$33.00M
YoY Change	-30.3%	26.92%
% of Operating Profit	8.21%	14.86%
Other Income/Expense, Net	-$20.00M	-$43.00M
YoY Change	-53.49%	-187.76%
Pretax Income	$260.0M	$179.0M
YoY Change	45.25%	36.64%
Income Tax	$62.00M	$72.00M
% Of Pretax Income	23.85%	40.22%
Net Earnings	$198.0M	$107.0M
YoY Change	85.05%	38.96%
Net Earnings / Revenue	4.81%	2.3%
Basic Earnings Per Share	$3.19	$1.79
Diluted Earnings Per Share	$2.99	$1.64
COMMON SHARES
Basic Shares Outstanding	62.10M shares	59.80M shares
Diluted Shares Outstanding	66.20M shares	65.20M shares

Balance Sheet

Concept	2019 Q1	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.732B	$6.173B
YoY Change	-23.34%	17.49%
Cash & Equivalents	$3.224B	$3.729B
Short-Term Investments	$1.508B	$2.444B
Other Short-Term Assets	$640.0M	$1.073B
YoY Change	-40.35%	655.63%
Inventory
Prepaid Expenses
Receivables	$1.359B	$950.0M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$6.731B	$8.196B
YoY Change	-17.87%	28.02%
LONG-TERM ASSETS
Property, Plant & Equipment	$376.0M	$318.0M
YoY Change	18.24%	-28.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$111.0M	$135.0M
YoY Change	-17.78%	213.95%
Total Long-Term Assets	$848.0M	$937.0M
YoY Change	-9.5%	-42.73%
TOTAL ASSETS
Total Short-Term Assets	$6.731B	$8.196B
Total Long-Term Assets	$848.0M	$937.0M
Total Assets	$7.579B	$9.133B
YoY Change	-17.02%	13.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$406.0M	$713.0M
YoY Change	-43.06%	62.79%
Accrued Expenses	$31.00M
YoY Change
Deferred Revenue	$207.0M
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$205.0M	$566.0M
YoY Change	-63.78%	56500.0%
Total Short-Term Liabilities	$4.292B	$6.005B
YoY Change	-28.53%	35.8%
LONG-TERM LIABILITIES
Long-Term Debt	$1.121B	$1.318B
YoY Change	-14.95%	-20.27%
Other Long-Term Liabilities	$97.00M	$59.00M
YoY Change	64.41%	34.09%
Total Long-Term Liabilities	$1.218B	$1.377B
YoY Change	-11.55%	-18.86%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.292B	$6.005B
Total Long-Term Liabilities	$1.218B	$1.377B
Total Liabilities	$5.744B	$7.580B
YoY Change	-24.22%	20.11%
SHAREHOLDERS EQUITY
Retained Earnings	$1.295B	$412.0M
YoY Change	214.32%	-53.55%
Common Stock	$543.0M	$1.153B
YoY Change	-52.91%	37.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.835B	$1.553B
YoY Change
Total Liabilities & Shareholders Equity	$7.579B	$9.133B
YoY Change	-17.02%	13.62%

Cashflow Statement

Concept	2019 Q1	2018 Q1
OPERATING ACTIVITIES
Net Income	$198.0M	$107.0M
YoY Change	85.05%	38.96%
Depreciation, Depletion And Amortization	$25.00M	$37.00M
YoY Change	-32.43%	-24.49%
Cash From Operating Activities	$249.0M	$394.0M
YoY Change	-36.8%	-45.2%
INVESTING ACTIVITIES
Capital Expenditures	$6.000M	$4.000M
YoY Change	50.0%	-84.62%
Acquisitions
YoY Change
Other Investing Activities	$4.000M	$5.000M
YoY Change	-20.0%	-16.67%
Cash From Investing Activities	$171.0M	$145.0M
YoY Change	17.93%	-143.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$48.00M	-$5.000M
YoY Change	860.0%	400.0%
NET CHANGE
Cash From Operating Activities	$249.0M	$394.0M
Cash From Investing Activities	$171.0M	$145.0M
Cash From Financing Activities	-$48.00M	-$5.000M
Net Change In Cash	$372.0M	$534.0M
YoY Change	-30.34%	40.16%
FREE CASH FLOW
Cash From Operating Activities	$249.0M	$394.0M
Capital Expenditures	$6.000M	$4.000M
Free Cash Flow	$243.0M	$390.0M
YoY Change	-37.69%	-43.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q1	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
CY2019Q1	dei	Document Type DocumentType	10-Q
CY2019Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001179929
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	62619000	shares
CY2019Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2019Q1	dei	Entity Registrant Name EntityRegistrantName	MOLINA HEALTHCARE INC
CY2019Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2019Q1	dei	Trading Symbol TradingSymbol	moh
CY2018Q4	moh	Affordable Care Act Premium Stabilization Program Risk Adjustment Payable AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable	-466000000	USD
CY2019Q1	moh	Affordable Care Act Premium Stabilization Program Risk Adjustment Payable AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable	-568000000	USD
CY2018Q4	moh	Affordable Care Act Premium Stabilization Program Risk Adjustment Receivable AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable	34000000	USD
CY2019Q1	moh	Affordable Care Act Premium Stabilization Program Risk Adjustment Receivable AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable	51000000	USD
CY2018Q1	moh	Amortization Of Debt Discount Premium And Sale Leaseback Financing Obligation AmortizationOfDebtDiscountPremiumAndSaleLeasebackFinancingObligation	7000000	USD
CY2019Q1	moh	Amortization Of Debt Discount Premium And Sale Leaseback Financing Obligation AmortizationOfDebtDiscountPremiumAndSaleLeasebackFinancingObligation	3000000	USD
CY2018Q1	moh	Amount Of Current Year Quality Incentive Premium Revenue Recognized AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized	24000000	USD
CY2019Q1	moh	Amount Of Current Year Quality Incentive Premium Revenue Recognized AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized	26000000	USD
CY2018Q1	moh	Amount Of Quality Incentive Premium Revenue Recognized From Prior Year AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear	11000000	USD
CY2019Q1	moh	Amount Of Quality Incentive Premium Revenue Recognized From Prior Year AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear	20000000	USD
CY2018Q4	moh	Amounts Dueto Government Agencies Amounts Due State AmountsDuetoGovernmentAgenciesAmountsDueState	81000000	USD
CY2019Q1	moh	Amounts Dueto Government Agencies Amounts Due State AmountsDuetoGovernmentAgenciesAmountsDueState	90000000	USD
CY2018Q4	moh	Amounts Dueto Government Agencies Cost Sharing Reduction AmountsDuetoGovernmentAgenciesCostSharingReduction	183000000	USD
CY2019Q1	moh	Amounts Dueto Government Agencies Cost Sharing Reduction AmountsDuetoGovernmentAgenciesCostSharingReduction	0	USD
CY2018Q4	moh	Amounts Dueto Government Agencies Medical Cost Floorsand Corridors AmountsDuetoGovernmentAgenciesMedicalCostFloorsandCorridors	103000000	USD
CY2019Q1	moh	Amounts Dueto Government Agencies Medical Cost Floorsand Corridors AmountsDuetoGovernmentAgenciesMedicalCostFloorsandCorridors	98000000	USD
CY2018Q4	moh	Amounts Dueto Government Agencies Other AmountsDuetoGovernmentAgenciesOther	134000000	USD
CY2019Q1	moh	Amounts Dueto Government Agencies Other AmountsDuetoGovernmentAgenciesOther	176000000	USD
CY2018Q4	moh	Amounts Dueto Government Agencies Risk Adjustment AmountsDuetoGovernmentAgenciesRiskAdjustment	466000000	USD
CY2019Q1	moh	Amounts Dueto Government Agencies Risk Adjustment AmountsDuetoGovernmentAgenciesRiskAdjustment	568000000	USD
CY2018Q1	moh	Antidilutive Securities Excludedfrom Computationof Eps Share Based Compensation Amount AntidilutiveSecuritiesExcludedfromComputationofEPSShareBasedCompensationAmount	400000	shares
CY2019Q1	moh	Antidilutive Securities Excludedfrom Computationof Eps Share Based Compensation Amount AntidilutiveSecuritiesExcludedfromComputationofEPSShareBasedCompensationAmount	100000	shares
CY2018Q4	moh	Capitation Claims Payable CapitationClaimsPayable	52000000	USD
CY2019Q1	moh	Capitation Claims Payable CapitationClaimsPayable	59000000	USD
CY2018Q1	moh	Cash Paid For Settlement Of Conversion Option CashPaidForSettlementOfConversionOption	0	USD
CY2019Q1	moh	Cash Paid For Settlement Of Conversion Option CashPaidForSettlementOfConversionOption	115000000	USD
CY2019Q1	moh	Finance Lease Cost FinanceLeaseCost	8000000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	643000000	USD
CY2019Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	543000000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	108000000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	0	USD
CY2018Q1	moh	Health Care Organization Insurer Fee Expense HealthCareOrganizationInsurerFeeExpense	75000000	USD
CY2019Q1	moh	Health Care Organization Insurer Fee Expense HealthCareOrganizationInsurerFeeExpense	0	USD
CY2018Q1	moh	Health Care Organization Insurer Fee Revenue HealthCareOrganizationInsurerFeeRevenue	61000000	USD
CY2019Q1	moh	Health Care Organization Insurer Fee Revenue HealthCareOrganizationInsurerFeeRevenue	0	USD
CY2018Q1	moh	Health Care Organization Premium Tax Revenue HealthCareOrganizationPremiumTaxRevenue	104000000	USD
CY2019Q1	moh	Health Care Organization Premium Tax Revenue HealthCareOrganizationPremiumTaxRevenue	138000000	USD
CY2018Q1	moh	Increase Decrease In Medical Premium Liability Due To Agency IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency	172000000	USD
CY2019Q1	moh	Increase Decrease In Medical Premium Liability Due To Agency IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency	-35000000	USD
CY2019Q1	moh	Investments Maturity Period InvestmentsMaturityPeriod	P10Y
CY2018Q4	moh	Liabilityfor Unpaid Claimsand Claims Adjustment Expense Incurredbut Not Paid Ibnp Feeforservice Claims Amount LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount	1562000000	USD
CY2019Q1	moh	Liabilityfor Unpaid Claimsand Claims Adjustment Expense Incurredbut Not Paid Ibnp Feeforservice Claims Amount LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount	1411000000	USD
CY2018Q1	moh	Maximum Available Quality Incentive Premium Current Year MaximumAvailableQualityIncentivePremiumCurrentYear	40000000	USD
CY2019Q1	moh	Maximum Available Quality Incentive Premium Current Year MaximumAvailableQualityIncentivePremiumCurrentYear	45000000	USD
CY2018Q4	moh	Medical Claims And Benefits Payable MedicalClaimsAndBenefitsPayable	107000000	USD
CY2019Q1	moh	Medical Claims And Benefits Payable MedicalClaimsAndBenefitsPayable	278000000	USD
CY2018Q1	moh	Medical Claims And Benefits Payable Adjustments Change In Provider MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider	45000000	USD
CY2019Q1	moh	Medical Claims And Benefits Payable Adjustments Change In Provider MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider	171000000	USD
CY2018Q4	moh	Medical Premium Liability Due To Agency MedicalPremiumLiabilityDueToAgency	967000000	USD
CY2019Q1	moh	Medical Premium Liability Due To Agency MedicalPremiumLiabilityDueToAgency	932000000	USD
CY2018Q1	moh	Noncash Restructuring Charges NoncashRestructuringCharges	17000000	USD
CY2019Q1	moh	Noncash Restructuring Charges NoncashRestructuringCharges	0	USD
CY2018Q1	moh	Notes Issued Fair Value Adjustment Increase Decrease NotesIssuedFairValueAdjustmentIncreaseDecrease	-23000000	USD
CY2019Q1	moh	Notes Issued Fair Value Adjustment Increase Decrease NotesIssuedFairValueAdjustmentIncreaseDecrease	0	USD
CY2018Q4	moh	Other Claims Payable OtherClaimsPayable	232000000	USD
CY2019Q1	moh	Other Claims Payable OtherClaimsPayable	411000000	USD
CY2018Q4	moh	Pharmacy Claims Payable PharmacyClaimsPayable	115000000	USD
CY2019Q1	moh	Pharmacy Claims Payable PharmacyClaimsPayable	114000000	USD
CY2018Q1	moh	Premium Tax Expenses PremiumTaxExpenses	104000000	USD
CY2019Q1	moh	Premium Tax Expenses PremiumTaxExpenses	138000000	USD
CY2018Q1	moh	Quality Incentive Premium Revenue As A Percentage Of Total Revenue QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue	0.008
CY2019Q1	moh	Quality Incentive Premium Revenue As A Percentage Of Total Revenue QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue	0.012
CY2018Q1	moh	Quality Incentive Premium Revenue Recognized QualityIncentivePremiumRevenueRecognized	35000000	USD
CY2019Q1	moh	Quality Incentive Premium Revenue Recognized QualityIncentivePremiumRevenueRecognized	46000000	USD
CY2018Q1	moh	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue	37000000	USD
CY2019Q1	moh	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue	48000000	USD
CY2019Q1	moh	Unrecognized Compensation Forfeited Rate UnrecognizedCompensationForfeitedRate	0.141
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	390000000	USD
CY2019Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	444000000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8000000	USD
CY2019Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3000000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-103000000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3824000000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2926000000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3224000000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3290000000	USD
CY2018Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	7000000	USD
CY2019Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3000000	USD
CY2018Q4	us-gaap	Assets Assets	7154000000	USD
CY2019Q1	us-gaap	Assets Assets	7579000000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	6462000000	USD
CY2019Q1	us-gaap	Assets Current AssetsCurrent	6731000000	USD
CY2018Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	2157000000	USD
CY2019Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	2024000000	USD
CY2019Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000000	USD
CY2019Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5000000	USD
CY2019Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1512000000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	12000000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	12000000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	550000000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	547000000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost	23000000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	23000000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	927000000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	926000000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue	1508000000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1508000000	USD
CY2018Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	1000000	USD
CY2019Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	0	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3729000000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2826000000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3298000000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	534000000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	372000000	USD
CY2013Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	53.8475
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2019Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62000000	shares
CY2019Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63000000	shares
CY2018Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	0	USD
CY2019Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	0	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	101000000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	203000000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	211000000	USD
CY2019Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	207000000	USD
CY2018Q1	us-gaap	Costs And Expenses CostsAndExpenses	4424000000	USD
CY2019Q1	us-gaap	Costs And Expenses CostsAndExpenses	3839000000	USD
CY2019Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	22000000	USD
CY2019Q1	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	9000000	USD
CY2018Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	117000000	USD
CY2019Q1	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	16000000	USD
CY2019Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	172000000	USD
CY2019Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	76000000	USD
CY2018Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	26000000	USD
CY2019Q1	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	12000000	USD
CY2013	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	13500000	shares
CY2019Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1336000000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	694000000	USD
CY2019Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	612000000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	8000000	USD
CY2019Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	4000000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	516	Security
CY2019Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	442	Security
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	509000000	USD
CY2019Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	207000000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	3000000	USD
CY2019Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	1000000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	285	Security
CY2019Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	96	Security
CY2018Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	1000000	USD
CY2019Q1	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	1000000	USD
CY2018Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	10000000	USD
CY2019Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	25000000	USD
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	37000000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	25000000	USD
CY2018Q4	us-gaap	Derivative Assets Current DerivativeAssetsCurrent	476000000	USD
CY2019Q1	us-gaap	Derivative Assets Current DerivativeAssetsCurrent	516000000	USD
CY2018Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2019Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2018Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	476000000	USD
CY2019Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	516000000	USD
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.79
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.19
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.64
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.99
CY2019Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	71000000	USD
CY2019Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	4000000	USD
CY2019Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	4000000	USD
CY2019Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	241000000	USD
CY2019Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	7000000	USD
CY2018Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	197000000	USD
CY2019Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	234000000	USD
CY2019Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	413000000	USD
CY2019Q1	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	311000000	USD
CY2019Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1000000	USD
CY2019Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	237000000	USD
CY2019Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	4000000	USD
CY2019Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	3000000	USD
CY2019Q1	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	21000000	USD
CY2019Q1	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	21000000	USD
CY2019Q1	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	22000000	USD
CY2019Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.066
CY2019Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P17Y
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-30000000	USD
CY2018Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-10000000	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	352000000	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	302000000	USD
CY2019Q1	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount	100000000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	179000000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	260000000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	72000000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	62000000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	319000000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	78000000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	43000000	USD
CY2018Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	130000000	USD
CY2019Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-4000000	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	6000000	USD
CY2019Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-15000000	USD
CY2018Q1	us-gaap	Increase Decrease In Health Care Insurance Liabilities IncreaseDecreaseInHealthCareInsuranceLiabilities	-163000000	USD
CY2019Q1	us-gaap	Increase Decrease In Health Care Insurance Liabilities IncreaseDecreaseInHealthCareInsuranceLiabilities	34000000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	239000000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-20000000	USD
CY2018Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	83000000	USD
CY2019Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	29000000	USD
CY2018Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	4400000	shares
CY2019Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	3500000	shares
CY2018Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	700000	shares
CY2019Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2018Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	300000	shares
CY2019Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	600000	shares
CY2018Q1	us-gaap	Insurance Services Revenue InsuranceServicesRevenue	134000000	USD
CY2019Q1	us-gaap	Insurance Services Revenue InsuranceServicesRevenue	0	USD
CY2018Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	190000000	USD
CY2019Q1	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	185000000	USD
CY2018Q1	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	24000000	USD
CY2019Q1	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	29000000	USD
CY2018Q1	us-gaap	Interest Expense InterestExpense	33000000	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	23000000	USD
CY2018Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	9000000	USD
CY2019Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	4000000	USD
CY2018Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	2000000	USD
CY2019Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1000000	USD
CY2019Q1	us-gaap	Lessee Finance Lease Renewal Term1 LesseeFinanceLeaseRenewalTerm1	P25Y
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	103000000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	9000000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	9000000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	12000000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	18000000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	28000000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	27000000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	10000000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P10Y
CY2019Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P10Y
CY2018Q4	us-gaap	Liabilities Liabilities	5507000000	USD
CY2019Q1	us-gaap	Liabilities Liabilities	5744000000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7154000000	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7579000000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4246000000	USD
CY2019Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4292000000	USD
CY2018Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	476000000	USD
CY2019Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	516000000	USD
CY2017Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	2192000000	USD
CY2018Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	2023000000	USD
CY2018Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	1961000000	USD
CY2019Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	1995000000	USD
CY2018Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	2498000000	USD
CY2019Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	2197000000	USD
CY2018Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	1438000000	USD
CY2019Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	1311000000	USD
CY2018Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	3722000000	USD
CY2019Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	3371000000	USD
CY2018Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	241000000	USD
CY2019Q1	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	198000000	USD
CY2019Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	330000000	USD
CY2019Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	70000000	USD
CY2019Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	10000000	USD
CY2019Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	710000000	USD
CY2019Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	7000000	USD
CY2019Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	209000000	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1020000000	USD
CY2019Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1121000000	USD
CY2018Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1681000000	USD
CY2019Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1508000000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5000000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-48000000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	145000000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	171000000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	394000000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	249000000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	107000000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	198000000	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-43000000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-20000000	USD
CY2018Q1	us-gaap	Notes Issued1 NotesIssued1	131000000	USD
CY2019Q1	us-gaap	Notes Issued1 NotesIssued1	0	USD
CY2019Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	Segment
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	222000000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	280000000	USD
CY2019Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	9000000	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	93000000	USD
CY2019Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	31000000	USD
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	62000000	USD
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	9000000	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	83000000	USD
CY2019Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.055
CY2019Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	24000000	USD
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	111000000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-6000000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	5000000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-7000000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	7000000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-1000000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	2000000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	44000000	USD
CY2019Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	97000000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10000000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3000000	USD
CY2018Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	2000000	USD
CY2019Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	3000000	USD
CY2018Q1	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	3936000000	USD
CY2019Q1	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	3508000000	USD
CY2018Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	5000000	USD
CY2019Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	4000000	USD
CY2018Q1	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	0	USD
CY2019Q1	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	103000000	USD
CY2018Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	389000000	USD
CY2019Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	185000000	USD
CY2018Q1	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	0	USD
CY2019Q1	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	46000000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4000000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6000000	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2019Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	4323000000	USD
CY2019Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	3952000000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	149000000	USD
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	124000000	USD
CY2018Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2019Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	115000000	USD
CY2018Q1	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	0	USD
CY2019Q1	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	100000000	USD
CY2018Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-5000000	USD
CY2019Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	1000000	USD
CY2018Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	543000000	USD
CY2019Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	366000000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	241000000	USD
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	376000000	USD
CY2018Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	1330000000	USD
CY2019Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	1359000000	USD
CY2018Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	95000000	USD
CY2019Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	74000000	USD
CY2018Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	120000000	USD
CY2019Q1	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	100000000	USD
CY2018Q1	us-gaap	Restructuring Costs RestructuringCosts	25000000	USD
CY2019Q1	us-gaap	Restructuring Costs RestructuringCosts	3000000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1012000000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1295000000	USD
CY2018Q1	us-gaap	Revenues Revenues	4646000000	USD
CY2019Q1	us-gaap	Revenues Revenues	4119000000	USD
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	241000000	USD
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	94000000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6000000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	9000000	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	18360	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	74.03
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	354172	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	137.37
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	604310	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	806468	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	71.50
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	100.91
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	133654	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	15000000	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	18000000	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	68.24
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2017Q4	us-gaap	Shares Outstanding SharesOutstanding	59300000	shares
CY2018Q4	us-gaap	Shares Outstanding SharesOutstanding	62100000	shares
CY2018Q1	us-gaap	Stock Issued1 StockIssued1	5000000	USD
CY2019Q1	us-gaap	Stock Issued1 StockIssued1	7000000	USD
CY2019Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2018Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1000000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3000000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	1647000000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	1835000000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1337000000	USD
CY2018Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1553000000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1647000000	USD
CY2019Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1835000000	USD
CY2018Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	4033000000	USD
CY2019Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	3560000000	USD
CY2018Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-311000000	USD
CY2019Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-189000000	USD
CY2018Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	65200000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	66200000	shares
CY2018Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	500000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	0	shares
CY2018Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59800000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62100000	shares
CY2019Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with a maximum maturity of </font><font style="font-family:Arial;font-size:10pt;">10</font><font style="font-family:Arial;font-size:10pt;"> years. Restricted investments are invested principally in certificates of deposit and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is generally limited because our payors consist principally of the governments of each state in which our health plan subsidiaries operate. </font></div></div>
CY2019Q1	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table provides the details of our medical claims and benefits payable as of the dates indicated.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">March 31, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,<br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Fee-for-service claims incurred but not paid (“IBNP”)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,411</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,562</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Pharmacy payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">114</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">115</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Capitation payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">59</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">411</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">232</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,995</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,961</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>
CY2019Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The preparation of consolidated financial statements in conformity with generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Principal areas requiring the use of estimates include:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The determination of medical claims and benefits payable of our Health Plans segment;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Health plans’ contractual provisions that may limit revenue recognition based upon the costs incurred or the profits realized under a specific contract;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Health plans’ quality incentives that allow us to recognize incremental revenue if certain quality standards are met;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Settlements under risk or savings sharing programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The assessment of long-lived and intangible assets, and goodwill for impairment;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The determination of reserves for potential absorption of claims unpaid by insolvent providers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The determination of reserves for litigation outcomes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The determination of valuation allowances for deferred tax assets; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The determination of unrecognized tax benefits. </font></div></td></tr></table></div>

Files In Submission

Name	View Source	Status
0001179929-19-000082-index-headers.html	Edgar Link	pending
0001179929-19-000082-index.html	Edgar Link	pending
0001179929-19-000082.txt	Edgar Link	pending
0001179929-19-000082-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
moh-03312019x10q.htm	Edgar Link	pending
moh-03312019xex311.htm	Edgar Link	pending
moh-03312019xex312.htm	Edgar Link	pending
moh-03312019xex321.htm	Edgar Link	pending
moh-03312019xex322.htm	Edgar Link	pending
moh-20190331.xml	Edgar Link	completed
moh-20190331.xsd	Edgar Link	pending
moh-20190331_cal.xml	Edgar Link	unprocessable
moh-20190331_def.xml	Edgar Link	unprocessable
moh-20190331_lab.xml	Edgar Link	unprocessable
moh-20190331_pre.xml	Edgar Link	unprocessable
molinalogo2016a26.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MOH
MOLINA HEALTHCARE, INC. Stock $moh

2019 Q1 Form 10-Q Financial Statement

#000117992919000082 Filed on April 30, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MOH MOLINA HEALTHCARE, INC. Stock $moh

2019 Q1 Form 10-Q Financial Statement

#000117992919000082 Filed on April 30, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MOH
MOLINA HEALTHCARE, INC. Stock $moh